Madrigal Pharmaceuticals, INC 10-Q quarterly reports

Madrigal Pharmaceuticals reports significant revenue increase driven by Rezdiffra sales, alongside substantial investments in pipeline expansion and commercialization efforts.

Madrigal Pharmaceuticals reported a significant increase in Rezdiffra net product revenue for Q1 2026, alongside substantial investments in pipeline expansion through new licensing agreements.

Madrigal Pharmaceuticals, Inc. announced significant revenue growth for Rezdiffra, its MASH treatment, following FDA and EC approvals, while also expanding its pipeline with a new GLP-1 receptor agonist.

Madrigal Pharmaceuticals reports significant revenue growth for Rezdiffra, advances European market entry, and expands its pipeline with a new GLP-1 asset.

Madrigal Pharmaceuticals reports $137.25 million in net product revenue for Q1 2025 following the FDA approval and commercial launch of Rezdiffra for MASH.

Madrigal Pharmaceuticals reported its first product revenue of $62.2 million in the third quarter of 2024, following the commercial launch of Rezdiffra in April.

Madrigal Pharmaceuticals reported its first product revenue of $14.6 million following the launch of Rezdiffra in April 2024, while also experiencing increased operating expenses related to commercialization efforts.

Madrigal Pharmaceuticals reports a net loss of $147.5 million for the first quarter of 2024, alongside the FDA approval and launch of Rezdiffra.